Movers and SHAKERS
Helius Medical Technologies (HSDT)(HSM:CA)
3Q21 Results; Raises $9.8 million, net
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
3Q21 Operating Results. Revenue of $109,000 and a net loss of $4.7 million, or $2.01 per share. This compares to revenue of $131,000 and a net loss of $3.5 million, or $2.70 per share, in the third quarter last year. (Share count increased to 2.4 million from 1.3 million y-o-y.) We had forecast revenue of $79,000 and a net loss $4.2 million, or $1.75 per share.
Early Days. Helius remains in the top of the first inning in terms of PoNS commercialization. The better than expected revenue is due to a slow re-opening of Canada from COVID restrictions. The Company has established 36 clinics throughout the country. The main difference in the loss is due to $0.9 million of severance cost related to the former CFO ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.